David A. Siegel Theseus Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$2.12 - $4.18 $12,084 - $23,826
5,700 Added 46.72%
17,900 $72,000
Q3 2023

Nov 14, 2023
SELL
$2.66 - $10.04 $47,880 - $180,719
-18,000 Reduced 59.6%
12,200 $32,000
Q2 2023

Aug 14, 2023
BUY
$7.28 - $11.82 $13,104 - $21,276
1,800 Added 6.34%
30,200 $281,000
Q1 2023

May 15, 2023
BUY
$5.21 - $14.05 $147,964 - $399,020
28,400 New
28,400 $252,000

Others Institutions Holding THRX

# of Institutions
2
Shares Held
1.03M
Call Options Held
0
Put Options Held
0
View Full List

About Theseus Pharmaceuticals, Inc.

THRX Quotes by TradingView
  • Ticker THRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,713,400
  • Description
  • Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...
More about THRX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email